Page last updated: 2024-12-06

motapizone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

motapizone: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65819
CHEMBL ID2104670
SCHEMBL ID385669
MeSH IDM0145966

Synonyms (31)

Synonym
motapizone
nat-5239
3-(4-imidazol-1-ylthiophen-2-yl)-4-methyl-4,5-dihydro-1h-pyridazin-6-one
motapizona [spanish]
motapizonum
motapizon
(rs)-4,5-dihydro-6-(4-imidazol-1-yl-2-thienyl)-5-methyl-3(2h)-pyridazinon
motapizone [inn]
motapizona
(+-)-4,5-dihydro-6-(4-imidazol-1-yl-2-thienyl)-5-methyl-3(2h)-pyridazinone
unii-c4a61p8a37
90697-57-7
nat 05-239
c4a61p8a37 ,
motapizonum [latin]
3(2h)-pyridazinone, 4,5-dihydro-6-(4-imidazol-1-yl-2-thienyl)-5-methyl-
CHEMBL2104670
nat-05-239
3(2h)-pyridazinone, 4,5-dihydro-6-(4-(1h-imidazol-1-yl)-2-thienyl)-5-methyl-, (+/-)-
3(2h)-pyridazinone, 4,5-dihydro-6-(4-(1h-imidazol-1-yl)-2-thienyl)-5-methyl-
(+/-)-4,5-dihydro-6-(4-imidazol-1-yl-2-thienyl)-5-methyl-3(2h)-pyridazinone
93749-03-2
SCHEMBL385669
AKOS033546220
Q27275177
DTXSID30869061
6-[4-(1h-imidazol-1-yl)thiophen-2-yl]-5-methyl-4,5-dihydropyridazin-3(2h)-one
CS-0026457
EN300-132692
6-[4-(1h-imidazol-1-yl)thiophen-2-yl]-5-methyl-2,3,4,5-tetrahydropyridazin-3-one
HY-106739

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Pre-treatment with motapizone, RP73401, rolipram or the methylxanthine adenosine receptor antagonist, 8-phenyltheophylline, did not significantly decrease responses to either allergen or LTC(4)."( The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C(4)-induced contractions in passively sensitized human airways.
Branscheid, D; Dent, G; Magnussen, H; Rabe, KF; Rühlmann, E; Schmidt, DT; Watson, N, 2000
)
0.63
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (23.53)18.7374
1990's7 (41.18)18.2507
2000's4 (23.53)29.6817
2010's2 (11.76)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (5.88%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (94.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]